ZEVTERA

Growth

ceftobiprole medocaril sodium

NDAINTRAVENOUSPOWDERPriority Review
Approved
Apr 2024
Lifecycle
Growth
Competitive Pressure
18/100

Loss of Exclusivity

LOE Date
Apr 3, 2029
37 months away
Exclusivity Expiry
Apr 3, 2034
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers